Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution

European Journal of Cancer Part A

Volumn 32, Issue 7, 1996, Pages 1135-1141

  Buccheri, G ^a   Ferrigno, D ^a   Tamburini, M ^a  

^a NONE

Author keywords

bronchogenic carcinoma; performance status scoring; predictive validity; scale equivalence

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LUNG CANCER; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 0030176378     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00664-8     Document Type: Article

References (28)

1. 1. Minna JD, Higgins GA, Glatstein EJ. Cancer of the lung. In De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, J.B. Uppincott Co., 1985, 507-597.
2. 2. Orr ST, Aisner J. Performance status assessment among oncology patients: a review. Cancer Treat Rep 1986, 70, 1423-1429.
3. 3. Tummarello D, Graziano F, Isidori P, Cellerino R. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol 1995, 35, 249-253.
4. 4. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 1991, 67, 3131-3135.
5. 5. Capewell S, Sudlow MF. Performance and prognosis in patients with lung cancer. Thorax 1990, 45, 951-956.
6. 6. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Resp J 1994, 7, 1350-1364.
7. 7. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York, Columbia University Press, 1949, 199-205.
8. 8. Zubrod CG, Scheiderman MA, Frei E, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960, 11, 7-33.
9. 9. Verger E, Salamero M, Conill C. Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group Scoring Scale and vice versa? Eur J Cancer 1992, 28A, 1328-1330.
10. 10. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer 1984, 53, 2002-2007.
11. 11. Coscarelli Schag C, Heinrich RL, Ganz PA. Karnofsky performance status revised: reliability, validity, and guidelines. J Clin Oncol 1984, 2, 187-193.
12. 12. Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer 1990, 65, 1864-1866.
13. 13. American Psychological Association. Standards for Educational and Psychological Tests. Washington, DC, APA, 1974.
14. 14. World Health Organisation. International Histological Classification of Tumours. Berlin, Springer, 1991.
15. 15. Buccheri GF, Violante B, Sartoris AM, Ferrigno D, Curcio A, Vola F. Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 1986, 57, 2389-2396.
16. 16. Buccheri GF, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma: superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer 1987, 60, 42-50.
17. 2 fragments of the anticarcinoembryonic antigen monoclonal antibody FO23C5. Cancer 1992, 70, 749-759.
18. 18. Buccheri G, Biggi A, Ferrigno D, Leone A, Taviani M, Quaranta M. Anti-CEA immunoscintigraphy might be more useful than computed tomography in the preoperative thoracic evaluation of lung cancer. Chest 1993, 104, 734-742.
19. 19. UICC. TNM Classification of Malignant Tumours. Berlin, Springer, 1987.
20. 20. Buccheri G, Ferrigno D, Rosso A. A Phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer. Cancer 1993, 72, 1564-1572.
21. 21. Buccheri G, Ferrigno D. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Eur J Cancer 1994, 30A, 1424-1431.
22. 22. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
23. 23. Kaplan EL, Meier F. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 58, 457-481.
24. 24. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II Analysis and examples. Br J Cancer 1977, 35, 1-39.
25. 25. Cox DR. Regression models and life tables. J R Stat Soc 1972, 34, 187-220.
26. 26. Siegel S. Nonparametric Statistics for the Behavioural Sciences. New York, MacGraw-Hill, 1956.
27. 27. American Joint Committee on Cancer. Purposes and principles of staging. In Beahrs OH, Earl Henson D, Hutter RVP, Myers MH, eds. Manual for Staging of Cancer. Philadelphia, J.B. Lippincott Co., 1988, 3-10.
28. 28. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993, 67, 773-775.